Articles

There is renewed interest in MSI analysis because the MSI-H/dMMR phenotype has emerged as an actionable predictive biomarker for immune checkpoint blockade therapy in different cancer types. This review presents available evidence supporting the clinical relevance and predictive value of MSI/dMMR in cancers, including those treated with immune checkpoint inhibitors (ICIs), and outlines the diagnostic approaches developed to assess MSI/dMMR in clinical practice. Read More ›

Genotyping tumors for microsatellite instability (MSI) has taken on new importance in the world of oncology. MSI screening has long been recognized as important in the care of patients with colorectal cancer (CRC) or endometrial cancer, and high-level MSI (MSI-H) is now being recognized as a potential marker for germline mutations in certain DNA mismatch-repair (MMR) genes that lead to the development of Lynch syndrome. Read More ›

Studies examining the landscape of MSI in various cancers have shown that different tumor types tend to exhibit instability at different microsatellite loci throughout the genome, and a PCR-based test that is limited to the evaluation of only 5 loci may not adequately capture this heterogeneity. Read More ›

“Treating financial toxicity at the patient level is similar to treating a symptom like fatigue,” said Yousuf Zafar. Read More ›

There are many ways to collect patient-reported information, such as the routine use of patient-reported outcomes in patient care, which provides value by alerting clinicians to symptoms and by improving communications, symptom control, and quality of life. Read More ›

“This is a right target, right drug issue, and results might change based on the type of testing you use. So in order for you to pick the right drug, you need to know your target,” said James L. Chen, MD, at the Oncology Nursing Society 2018 Congress. Read More ›